Design, synthesis, and structure-activity relationship study of a novel class of ORL1 receptor antagonists based on N-biarylmethyl spiropiperidine

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 13, 2008, Pages 3778-3782

  Yoshizumi, Takashi ^a   Miyazoe, Hiroshi ^a   Ito, Hirokatsu ^a   Tsujita, Tomohiro ^a   Takahashi, Hirobumi ^a   Asai, Masanori ^a   Ozaki, Satoshi ^a   Ohta, Hisashi ^a   Okamoto, Osamu ^a  

^a BANYU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Antagonist; hERG channel; N Biarylmethyl spiropiperidine; ORL1

Indexed keywords

1' [[1 (3 CHLOROPYRIDIN 2 YL) 1H PYRAZOL 4 YL]METHYL] 3H SPIRO 2 BENZOFURAN 1,4' PIPERIDINE; OPIATE ANTAGONIST; OPIATE RECEPTOR; PIPERIDINE DERIVATIVE; POTASSIUM CHANNEL;

ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG DESIGN; DRUG SYNTHESIS; HUMAN; NONHUMAN; STRUCTURE ACTIVITY RELATION;

BINDING, COMPETITIVE; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PIPERIDINES; PROTEIN BINDING; RECEPTORS, OPIOID; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 44849137530     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.05.036     Document Type: Article

References (29)

1. Meunie J.-C., Mollereau C., Toll L., Suaudeau C., Moisand C., Alvinerie P., Butour J.-L., Guillemot J.-C., Ferrara P., Monsarrat B., Mazargil H., Vassart G., Parmentier M., and Costentin J. Nature 377 (1995) 532
2. Reinscheid R.K., Nothacher H.-P., Bourson A., Ardati A., Henningsen R.A., Bunzow J.R., Grady D.K., Langen H., Monsma Jr. F.J., and Civelli O. Science 270 (1995) 792
3. Mogil J.S., Grisel J.E., Reinscheid R.K., Civelli O., Belknap J.K., and Grandy D.K. Neuroscience 75 (1996) 333
4. Manabe T., Noda Y., Mamiya T., Katagiri H., Houtani T., Nishi M., Noda T., Takahashi T., Sugimoto T., Nabeshima T., and Takeshima H. Nature 394 (1998) 577
5. Sandin J., Georgieva J., Schott P.A., Orgen S.O., and Terenius L. Eur. J. Neurosci. 9 (1997) 194
6. Yu T.P., Fein J., Phan T., Evans C.J., and Xie C.-W. Hippocampus 7 (1997) 88
7. Jenck F., Moreau J.-L., Martin J.R., Kilpatrick G.J., Reinscheid R.K., Monsma Jr. F.J., Nothacker H.-P., and Civelli O. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 14854
8. Champion H.C., and Katwitz P.J. Life Sci. 60 (1997) 241
9. Gumusel B., Hao Q., Hyman A., Chang J.-K., Kapusta D.R., and Lippton H. Life Sci. 60 (1997) 141
10. Ronzoni S., Peretto I., and Giardina G.A.M. Exp. Opin. Ther. Patents 11 (2001) 525 and the references cited therein
11. Nurulain Z. Life Sci. 73 (2003) 663
12. Bignan G.C., Connolly P.J., and Middleton S.A. Exp. Opin. Ther. Patents 15 (2005) 357
13. Kawamoto H., Ozaki S., Itoh Y., Miyaji M., Arai S., Nakashima H., Kato T., Ohta H., and Iwasawa Y. J. Med. Chem. 42 (1999) 5061
14. Ito, F.; Noguchi, H.; Ohashi, Y.; Kondo, H.; Yamagishi, T. WO 99/36421, 1999.
15. Kyle, D.; Goehring, R. R.; Shao, B. WO 01/39775 A1, 2001.
16. Okamoto O., Kobayashi K., Kawamoto H., Ito S., Satoh A., Kato T., Yamamoto I., Mizutani S., Hashimoto M., Shimizu A., Sakoh H., Nagatomi Y., Iwasawa Y., Takahashi H., Ishii Y., Ozaki S., and Ohta H. Bioorg. Med. Chem. Lett. 18 (2008) 3282
17. Shinkai H., Ito T., Iida T., Kitao Y., Yamada H., and Uchida I. J. Med. Chem. 43 (2000) 4667
18. Rover S., Adam G., Cesura A.M., Galley G., Jenck F., Monsma F.J., Wichmann J., and Dautzenberg F.M. J. Med. Chem. 43 (2000) 1329
19. Kolczweski S., Adam G., Cesura A.M., Jenck F., Hennig M., Oberhauser T., Poli S.M., Rossler F., Rover S., Wichmann J., and Dautzenberg F.M. J. Med. Chem. 46 (2003) 255
20. Thomsen C., and Hohlweg R. Br. J. Pharmacol. 131 (2000) 903
21. Ito, F.; Ohashi, Y. EP 0997464 A1, 2000.
22. Goto Y., Arai-Otsuki S., Tachibana Y., Ichikawa D., Ozaki S., Takahashi H., Iwasawa Y., Okamoto O., Okuda S., Ohta H., and Sagara T. J. Med. Chem. 49 (2006) 847
23. Yoshizumi, T.; Takahashi, H.; Miyazoe, H.; Sugimoto, Y.; Tsujita, T.; Kato, T.; Ito, H.; Kawamoto, H.; Hirayama, M.; Ichikawa, D.; Azuma-Kanoh, T.; Ozaki, S.; Shibata, Y.; Tani, T.; Chiba, M.; Ishii, Y.; Okuda, S.; Tadano, K.; Fukuroda, T.; Okamoto, O.; Ohta, H. J. Med. Chem., in press.
24. Seventy-eight kinds of aldehydes consist of the following structures: pyridine-substituted benzaldehydes (8 kinds), pyrimidine substituted benzaldehydes (4 kinds), 4-(1-pyrro)benzaldehyde, 4-(2-thiazolyl)benzaldehyde, 4-(1,2,3-thiadiazol-4-yl)benzaldehyde, 2-methyl-3-formyl-5-phenylfuran, 3-methyl-4-formyl-5-phenyl-1,2-oxazole, 2-methyl-3-formyl-4-phenyl-1,2-oxazole, 2-formyl-5-phenylthiophene, 2-formyl-5-(2-pyridyl)thiophene, 2-formyl-thiazoles with aromatic substituent (11 kinds), 4-formyl-2-phenylthiazole, 2-formylpyrroles with aromatic substituent at the 1-position (37 kinds), 1-(2-cyanophenyl)-3-formylpyrrole, 3-formylpyrazoles with aromatic substituent at the 1-position (6 kinds), 1-phenyl-5-formylpyrazole, 1-phenyl-4-formyl-1,2,3-triazole.
25. Lazareno S., and Birdsall N.J.M. Br. J. Pharmacol. 109 (1993) 1120
26. J-113,397. Kawamoto H., Ozaki S., Itoh Y., Miyaji M., Arai S., Nakashima H., Kato T., Ohta H., and Iwasawa Y. J. Med. Chem. 42 (1999) 5061 was used as an internal control across all assay plates for data validation
27. Rat microsomal (RM) and human microsomal (HM) stabilities were determined by percentage parent compound (1 μM) remaining after 30 min (37 °C) incubation with rat/human liver microsomes (0.25 mg protein/ml).
28. +.
29. Hochman J.H., Yamazaki M., Ohe T., and Lin J.H. Curr. Drug. Metab. 3 (2002) 257